Related posts

Founder of Scale AI and, since 2025, Chief AI Officer at Meta, where he leads the company’s superintelligence lab.

• Our readingkorrents.com

  AI has ended the David-versus-Goliath era of startups: a startup that properly embraces agents can now easily outcompete incumbents.

  startups

  Their words

  And now I actually think with the power of agents um and AI broadly speaking, it's much closer to Goliath versus Goliath. Like I think but maybe the startup is like a Mecca Goliath that is like vastly enhanced by the power of agents and AI and you know, the the large companies are the sort of like more traditional Goliath, so to speak. But I think that startups now like if you properly embrace AI agents and um figure out the way to leverage their strengths in the most like ambitious ways, you can easily outcompete incumbents.

  youtube.com

Researcher and science writer. Co-founder and editor at Works in Progress magazine, formerly a researcher at Our World in Data, and author of the Scientific Discovery newsletter on science, global health and medical innovation.

• Lovedrcmnd.app

  Genentech: The Beginnings of Biotech

  Their words

  This amazing book traces the development of genetic engineering, and how Herbert Boyer and Robert Swanson turned the science into a commercial product by developing recombinant insulin.

  scientificdiscovery.dev

German writer and historian; wrote Blitzed, on drug use in Nazi Germany, and Tripped.

• Our readingkorrents.com

  LSD is not a truth drug and never could be — it takes you toward your own truth, not out of it.

  energy

  Their words

  They miserably failed because LSD… Is not the truth drug. LSD maybe leads you closer to your own truth, because when suddenly the default mode network receives less energy and other parts of the brain think more, and the neuroplasticity of the brain is enhanced and stimulated, you might understand something about your life.

  youtube.com

Zurich-based value investor who ran the Aquamarine Fund from 1997 to 2025 and wrote The Education of a Value Investor. He hosts the VALUEx gathering in Klosters and publishes a podcast and newsletter.

• Our readingkorrents.com

  AI-enhanced access to information makes copying top investors' strategies smarter than ever before.

  Their words

  There is more access to information than ever before. And that access is only enhanced by AI. Times could not be better for shameless cloners.

  Long Live the Shameless Clonersguyspier.com

Writes about the biotech industry, drug development and forecasting — “I write to learn, mostly about biotech.”

• Our readingkorrents.com

  A computational discovery platform does not make a biotech fast, because the thousand other steps of drug development are still the bottleneck.

  Their words

  Another challenge for Class II biotechs is that even if you have a nifty computational drug discovery platform, you are still often bottlenecked by the rest of the drug development process. It takes 1,000 (or more!) small steps to advance a drug through discovery, development, and past the regulators.

  A new breed of biotechatelfo.github.io

Neuroscientist at UC Davis; studies memory and wrote Why We Remember.

• Our readingkorrents.com

  Torture and enhanced interrogation produce what the interrogator wants to hear rather than what happened, because stress shuts down the machinery that checks a memory's accuracy.

  Their words

  And from what I understand, the research actually shows that they just produce what people want to hear, not necessarily the information that is being looked for.

  youtube.com